GLP-3

Product Overview

A triple-agonist peptide engineered for simultaneous activity at three class B G-protein coupled receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This tri-agonist approach coordinates signaling across three receptor systems that individually regulate overlapping but distinct aspects of metabolic homeostasis.

Specifications

• Quantity: 10mg lyophilized powder
• Purity: ≥98% (HPLC verified)
• Manufacturing: Produced in a GMP-compliant facility in the USA
• Targets: GLP-1R, GIPR, and GCGR
• Appearance: White to off-white lyophilized powder
• Solubility: Soluble in water and PBS

Storage & Handling

• Store at -20°C for long-term storage
• Stable at 2-8°C for up to 21 days after reconstitution
• Protect from light
• Reconstitute with bacteriostatic water

Mechanism of Action

The triple-agonist engages three receptor-mediated pathways: (1) GLP-1R activation drives cAMP/PKA signaling in pancreatic beta cells and central anorexigenic circuits; (2) GIPR co-activation provides additive insulinotropic signaling and modulates adipose tissue lipid handling via cAMP-dependent pathways; (3) GCGR activation in hepatocytes stimulates glycogenolysis and gluconeogenesis via PKA-mediated phosphorylation of glycogen phosphorylase and CREB-dependent transcription of gluconeogenic enzymes (PEPCK, G6Pase). The glucagon receptor component also increases hepatic energy expenditure by upregulating mitochondrial fatty acid β-oxidation through FGF21-dependent and independent mechanisms. The net effect of coordinated tri-receptor engagement is a broader metabolic signaling footprint than achievable through single- or dual-agonism.

For Laboratory Use Only. Laboratory Use Only.

Quality Assurance: Each lot undergoes independent third-party LCMS/MS analysis. Certificates of Analysis are available on the product page.